Menicon Co., Ltd.
Stock Price Chart
2026/03/17 UpdatedPrice Trend
2026/03/17 UpdatedPrice & Trading Details
2026/03/17 UpdatedPRICE
TRADING
Analyst Recommendations 5 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
833.6K | -1.66% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
558.6K | +4.53% | |
|
Longleaf Partners Funds Trust-Longleaf Partners International Fund
|
550.4K | +2.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
534.8K | 0.00% | |
|
Artisan Partners Funds Inc.-Artisan International Small-Mid Fund
|
400.1K | -59.36% | |
|
Principal Funds, Inc-International Small Company Fund
|
347.4K | -3.29% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Legato Capital Management LLC
|
171.9K | 0.00% |
Dividend History 1Years Growth
Updated 2026/03/15| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥28 | +12.0% |
| 2024 | ¥25 | 0.0% |
| 2023 | ¥25 | +25.0% |
| 2022 | ¥20 | +14.3% |
| 2021 | ¥18 | - |
Financial Performance
2026/03/15 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥100,172M | ¥110,194M | ¥116,192M | ¥121,491M |
| Gross Profit | ¥52,879M | ¥58,474M | ¥61,010M | ¥65,080M |
| Operating Income | ¥9,957M | ¥12,063M | ¥8,952M | ¥10,052M |
| Pretax Income | ¥10,232M | ¥11,879M | ¥7,686M | ¥10,029M |
| Net Income | ¥6,481M | ¥7,377M | ¥4,538M | ¥5,621M |
| EPS | ¥79.08 | ¥89.78 | ¥55.17 | ¥69.15 |
| Operating Margin | 9.94% | 10.95% | 7.70% | 8.27% |
| Balance Sheet | ||||
| Total Assets | ¥130,978M | ¥152,522M | ¥179,812M | ¥187,282M |
| Total Equity | ¥66,993M | ¥74,611M | ¥81,747M | ¥86,094M |
| Total Liabilities | ¥63,985M | ¥77,911M | ¥98,065M | ¥101,188M |
| Cash | ¥33,046M | ¥41,249M | ¥46,911M | ¥42,046M |
| Interest-bearing Debt | ¥42,435M | ¥53,579M | ¥70,793M | ¥75,089M |
| Equity Ratio | 51.15% | 48.92% | 45.46% | 45.97% |
| D/E Ratio | 0.63 | 0.72 | 0.87 | 0.87 |
| Cash Flow | ||||
| Operating CF | ¥12,719M | ¥12,749M | ¥11,866M | ¥13,944M |
| Investing CF | -¥16,149M | -¥13,776M | -¥21,575M | -¥19,661M |
| Financing CF | -¥5,402M | ¥8,900M | ¥14,554M | ¥714M |
| Free CF | -¥3,227M | -¥226M | -¥9,468M | -¥3,544M |
| Efficiency | ||||
| ROE | 9.67% | 9.89% | 5.55% | 6.53% |
| ROA | 4.95% | 4.84% | 2.52% | 3.00% |
Latest IR Information
-
(Disclosure Progress) "Notice Regarding Acquisition of Shares of Itabashi Trading Co., Ltd. (Subsidiarization)" About Earnout Consideration and Accounting Treatment for Share Acquisition of Itabashi Trading Co., Ltd.
The accounting treatment of the earnout consideration related to the acquisition of shares of Itabashi Trading Co., Ltd. has changed from special loss to selling, general and administrative expenses, with a maximum of 500 million yen scheduled to be recorded...
Read more -
Notice Regarding Name Change of Consolidated Subsidiary
In early April 2026, the consolidated subsidiary Dalian Banqiao Medical Device Co., Ltd. will change its trade name to "Medicon (Dalian) Medical Technology Co., Ltd.", aiming to strengthen its brand strategy in the Chinese market.
Read more -
Presentation Material for the Third Quarter Financial Results for the Fiscal Year Ending March 2026
For the third quarter of the fiscal year ending March 2026, net sales were 93.932 billion yen (Year-over-Year +2.6%), operating income was 8.999 billion yen (Year-over-Year +5.0%), and net income attributable to owners of the parent for the quarter was...
Read more -
Financial Summary for the Third Quarter of the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending March 2026, net sales were 93,932 million yen (2.6% increase YoY), operating income was 8,999 million yen (5.0% increase YoY), and net income attributable to owners of parent for the quarter...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,030
Rating Score: 2.00 (Based on 5 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Menicon Co., Ltd. manufactures and sells contact lenses and lens care products in Japan. The company offers its products to hospitals, eye clinics, contact lens retailers, eyeglass stores, and drug stores. It also exports its products. Menicon Co., Ltd. was incorporated in 1943 and is headquartered in Nagoya, Japan.
